Events

Virtual Cybersecurity B2B Meetings & Webinar
MAY
Mon
19
MAY
Tue
20
MAY
Wed
21

Starts in 1 week from now

Location

Online

Programmes
Security Cybersecurity

The Enterprise Europe Network and SeREN5, the HorizonEurope NCPs Network for Cluster 3 research Civil Security for Society organise a twofold Virtual Cybersecurity B2B event

The event consists of

  • a fully virtual B2B event where participants can profile their offers and requests of collaboration, first ideas to set-up consortia and good proposals, with the help of both Enterprise Europe Network and Horizon Europe Cluster 3 NCPs
  • a hands-on, awareness-raising webinar on the forthcoming calls on topics related to the cybersecurity (Destination - Increased Cybersecurity) by SeREN5 network representative (19 May 2025, 10.00-12.00).

Participation is free of charge, but mandatory via this link.

myOverview - sign up for personalised information

We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).

Stay informed about what matters to you. By signing up, you can opt in for e-mail notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).

Only for stakeholders located in Flanders

Event calendar

 

Testimonial

image of BEAT-AF - Ground-Breaking Electroporation-based intervention for Atrial Fibrillation treatment

BEAT-AF - Ground-Breaking Electroporation-based intervention for Atrial Fibrillation treatment

The Horizon2020 project BEAT-AF brings together 9 European renowned clinical centres in France, Belgium, Czechia, Germany and Austria. Together, the consortium strives to revolutionize Atrial Fibrillation (AF) treatment through catheter ablation and contribute to decrease the huge burden of AF in Europe. The BEAT-AF project kicked off in 2021 and will run until 2026. The department of electrophysiology of the AZ Sint-Jan Hospital in Bruges is partner in the project and has so far contributed to the pre-clinical development, the first in man studies and first registries of the revolutionary AF treatment put forward by the consortium. The first pilot studies show that the treatment is safe, effective and efficient.